ArticleTranslational andrology and urology2026
Assessing the patient reported outcomes (PROs) of enfortumab vedotin plus pembrolizumab versus platinum-based chemotherapy in patients with advanced urothelial carcinoma in the EV-302 study.
Tobechukwu J Okobi et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.